Angiosarcoma
MONDO:0016982A malignant tumor arising from the endothelial cells of the blood vessels. Microscopically, it is characterized by frequently open vascular anastomosing and branching channels. The malignant cells that line the vascular channels are spindle or epithelioid and often display hyperchromatic nuclei. Angiosarcomas most frequently occur in the skin and breast. Patients with long-standing lymphedema are at increased risk of developing angiosarcoma.
Also known as: angiosarcoma, angiosarcoma (disease), blood vessel sarcoma, hemangiosarcoma, hemangiosarcoma, malignant, malignant angioendothelioma, malignant hemangioendothelioma, sarcoma of blood vessel
2886 clinical trials for this condition and its sub-types, 37 tagged with Angiosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Angiosarcoma
-
Kaposi's sarcoma 45 trials
4 sub-types
- Classic Kaposi sarcoma 3 trials
- Endemic Kaposi sarcoma 1 trial
- Iatrogenic Kaposi's sarcoma 1 trial
- Colorectal Kaposi sarcoma 0 trials Sub-types →
-
Skin angiosarcoma 6 trials
-
Breast angiosarcoma 1 trial
-
Angiosarcoma of the scalp 0 trials
-
Aorta angiosarcoma 0 trials
-
Bone angiosarcoma 0 trials
-
Central nervous system angiosarcoma 0 trials
-
Conventional angiosarcoma 0 trials
-
Gallbladder angiosarcoma 0 trials
-
Liver angiosarcoma 0 trials
-
Mediastinum angiosarcoma 0 trials
-
Ovarian angiosarcoma 0 trials
-
Pediatric angiosarcoma 0 trials
-
Prostate angiosarcoma 0 trials
-
Pulmonary artery leiomyosarcoma 0 trials
-
Pulmonary vein leiomyosarcoma 0 trials
-
Spleen angiosarcoma 0 trials
-
Superior vena cava angiosarcoma 0 trials
1 sub-type
- Superior vena cava leiomyosarcoma 0 trials
-
Thyroid gland angiosarcoma 0 trials
Most studied deeper sub-types
-
New cocktail aims to shrink sarcomas: bevacizumab joins chemo in phase 2 trial
Disease control Not yet recruitingThis phase 2 trial tests whether adding the drug bevacizumab (Onbevzi) to standard chemotherapy (gemcitabine and docetaxel) can shrink tumors better than chemo alone in people with advanced soft tissue sarcoma. About 92 adults who have already had 1-2 prior chemotherapies will be…
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered t cells take on Hard-to-Treat cancers in new trial
Disease control Not yet recruitingThis early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC